ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes

Louise Bowman, Marion Mafham, William Stevens, Richard Haynes, Theingi Aung, Fang Chen, Georgina Buck, Rory Collins, Jane Armitage, ASCEND Study Collaborative Group, Louise Bowman, Marion Mafham, William Stevens, Richard Haynes, Theingi Aung, Fang Chen, Georgina Buck, Rory Collins, Jane Armitage, ASCEND Study Collaborative Group

Abstract

Objectives: The use of aspirin for the secondary prevention of cardiovascular disease (CVD) is firmly established, and the proportional reductions in heart attacks and strokes appear to be similar in people with and without diabetes. Uncertainty remains about the role of antiplatelet treatments for primary prevention of CVD, and guidelines vary in their recommendations. It has also been hypothesized that long-term aspirin can prevent gastro-intestinal and other cancers. Observational studies suggest associations between higher intakes of omega-3 fatty acids (FA) and lower rates of CVD, but there is no large-scale randomized evidence to support using prophylactic omega-3 FA supplementation in primary prevention. ASCEND is a randomized trial assessing whether 100 mg daily aspirin safely prevents CVD and cancer in patients with diabetes without known arterial disease. It is also assessing whether supplementation with 1 g omega-3 FA daily prevents CVD. This paper describes the methods and baseline characteristics of the randomized participants.

Methods and results: Between 2005 and 2011, using mail-based methods, 15,480 people with diabetes were randomized to aspirin versus placebo and, in a factorial design, to omega-3 FA supplementation versus placebo. Blood and urine samples were collected to allow baseline stratification by biochemical prognostic variables (e.g. HbA1c, blood lipids). Follow-up is for a median of at least 7 years.

Conclusions: Demonstrating that prophylactic aspirin safely reduces the risk of CVD or cancer in the primary prevention setting, or that omega-3 FA supplementation prevents CVD, would be relevant to hundreds of millions of people worldwide who are currently not receiving such therapies. The results of ASCEND will be reported in 2018.

Trial registration: ClinicalTrials.gov NCT00135226.

Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Figure
Figure
Trial profile: Flow of participants through the ASCEND trial.

References

    1. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
    1. Diabetes Atlas. 7th ed. International Diabetes Federation; 2015.
    1. Antithrombotic Trialists' Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.
    1. Sarwar N., Gao P., Seshasai S.R. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
    1. Belch J., MacCuish A., Campbell I. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
    1. Ogawa H., Nakayama M., Morimoto T. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–2141.
    1. Fowkes F.G., Price J.F., Stewart M.C. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–848.
    1. Ikeda Y., Shimada K., Teramoto T. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510–2520.
    1. Rothwell P.M., Price J.F., Fowkes F.G. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602–1612.
    1. Rothwell P.M., Wilson M., Elwin C.E. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–1750.
    1. Rothwell P.M., Wilson M., Price J.F. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–1601.
    1. Flossmann E., Rothwell P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–1613.
    1. Capodanno D., Angiolillo D.J. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation. 2016;134:1579–1594.
    1. Bang H.O., Dyerberg J., Nielsen A.B. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet. 1971;1:1143–1145.
    1. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–2757.
    1. Burr M.L., Fehily A.M., Gilbert J.F. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART) Lancet. 1989;2:757–761.
    1. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardicoLancet. 1999;354:447–455.
    1. Aung T., Halsey J., Kromhout D. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks. Meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018
    1. Report of a WHO/IDF consultation. 2006. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. [Contract No.: ISBN]
    1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62–S69.
    1. Aung T., Haynes R., Barton J. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND) Trials. 2016;17:286.
    1. Lang J.M., Buring J.E., Rosner B. Estimating the effect of the run-in on the power of the Physicians' Health Study. Stat Med. 1991;10:1585–1593.
    1. Prior M.J., Prout T., Miller D. C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group. Ann Epidemiol. 1993;3:9–17.
    1. Barton J., Young A., Lay M. Introduction of electronic data capture method using participant-completed online web-based follow up questionnaire in mail-based study achieves expected benefits and positive participant feedback. Trials. 2015;16:P44.
    1. Clark S., Youngman L.D., Palmer A. Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studies. Int J Epidemiol. 2003;32:125–130.
    1. Algra A.M., Rothwell P.M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–527.
    1. Rothwell P.M., Giles M.F., Chandratheva A. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007;370:1432–1442.
    1. Colwell J.A. Aspirin therapy in diabetes. Diabetes Care. 2004;27(Suppl 1):S72–3.
    1. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic AssociationHeart. 1998;80(Suppl. 2):S1–29.
    1. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J. 1998;19(Suppl A):A12–A19.
    1. National Institute for Health and Care Excellence . NICE guideline [NG28] 2015. Type 2 diabetes in adults: management.
    1. Piepoli M.F., Hoes A.W., Agewall S. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J. 2016;37:2315–2381.
    1. Bibbins-Domingo K. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement Aspirin Use for the Primary Prevention of CVD and CRC. Ann Intern Med. 2016;164:836–845.
    1. De Berardis G., Sacco M., Evangelista V. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.
    1. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trialContemp Clin Trials. 2013;36:555–564.
    1. ARRIVE study. 2016. Available from:

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj